Our findings reported that depletion of HMGA1 in a xenograft mouse model sensitizes BC cells to paclitaxel, which would indicate that taxol-based applications may be more effective in reducing the tumour burden when tumour cells express low levels of HMGA1 (Fig. 6D). This evidence concerns the gene HMGA1 and breast cancer.